Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500923 | 0.87 | — | — | |
| SCHEMBL4018597 | 0.87 | — | — | |
| SCHEMBL5870436 | 0.87 | — | — | |
| Glycolic Acid SCHEMBL10953166 | 0.87 | USP2 (0.32) | — | |
| Sulfuric Acid SCHEMBL11494938 | 0.84 | — | — | |
| SCHEMBL8939302 | 0.84 | — | — | |
| Acetic Acid SCHEMBL8939345 | 0.81 | — | — | |
| Nitric Acid SCHEMBL8939273 | 0.79 | GRM2 (0.33) | — | |
| Propionic Acid SCHEMBL8939283 | 0.78 | — | — | |
| Chloroacetic Acid SCHEMBL8939293 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1453517-B1 | PLATINUM DERIVATIVE PHARMACEUTICAL FORMULATIONS | PHARMACIA ITALIA SPA (IT) | 2006-02-08 | — | — | EP | claimed |
| US-20130101688-A1 | HERBAL COMPOSITION PHY906 AND ITS USE IN CHEMOTHERAPY | YALE UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-20100063145-A1 | ACID CONTAINING OXALIPLATIN FORMULATIONS | MAYNE PHARMA LIMITED | 2010-03-11 | — | — | US | disclosed |
| US-7534455-B2 | Herbal composition PHY906 and its use in chemotherapy | YALE UNIVERSITY (US) | 2009-05-19 | — | — | US | disclosed |
| EP-1561754-B1 | Process for preparing 1,2-Diaminocyclohexane-Platinum(II) complexes | HERAEUS GMBH W C (DE) | 2007-03-07 | — | — | EP | disclosed |
| US-20060264501-A1 | For parenteral administration containing oxaliplatin, water; and an acid, especially a di- or tricarboxylic acid such as tartaric acid or a sodium tartrate as a buffering agent that minimises significant degradation of oxaliplatin and limits the formation of unwanted impurities; cancer treatment | MAYNE PHARMA LIMITED (AU) | 2006-11-23 | — | — | US | disclosed |
| EP-1453517-B1 | PLATINUM DERIVATIVE PHARMACEUTICAL FORMULATIONS | PHARMACIA ITALIA SPA (IT) | 2006-02-08 | — | — | EP | disclosed |
| US-20050196473-A1 | Herbal composition PHY906 and its use in chemotherapy | KADMON CORPORATION, LLC | 2005-09-08 | — | — | US | disclosed |
| US-20030109515-A1 | Pharmaceutical formulation of a platinum derivative | PHARMACIA ITALIA, SPA. | 2003-06-12 | — | — | US | disclosed |
| US-6340770-B1 | COMPLEXES WITH DIAMINE COMPOUNDS WITH DIACIDS | SOOK MYUNG WOMEN'S UNIVERSITY (KR) | 2002-01-22 | — | — | US | disclosed |
| US-6306902-B1 | ANTICARCINOGENIC AGENTS | SANOFI-SYNTHELABO (FR) | 2001-10-23 | — | — | US | disclosed |
| EP-0943331-B1 | Formulations containing oxaliplatin | SANOFI SYNTHELABO (FR) | 2001-06-27 | — | — | EP | disclosed |
| EP-0943331-A2 | Formulations containing oxaliplatin | SANOFI (FR) | 1999-09-22 | — | — | EP | disclosed |